Verastem (VSTM) Assets Average (2012 - 2026)
Verastem's quarterly Assets Average came in at $237.1 million in Q1 2026, up 103.33% year-on-year from $116.6 million in Q1 2025, and up 12.04% quarter-over-quarter from $211.6 million in Q4 2025.
Verastem has reported Assets Average for 15 years, with the latest figure at $237.1 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 103.33% year-over-year to $237.1 million; the trailing twelve-month figure through Mar 2026 stood at $237.1 million (up 103.33% YoY), and the FY2025 full-year result was $174.0 million, up 38.5% from the prior year.
- Assets Average for Q1 2026 stood at $237.1 million, up from $211.6 million in the prior quarter.
- The five-year high for Assets Average was $237.1 million in Q1 2026, with the low at $103.1 million in Q4 2022.
- Average Assets Average over 5 years is $143.4 million, with a median of $116.6 million recorded in 2025.
- Year-over-year, Assets Average tumbled 36.91% in 2024 and jumped 103.33% in 2026.
- Tracing VSTM's Assets Average over 5 years: stood at $103.1 million in 2022, then surged by 58.08% to $162.9 million in 2023, then plunged by 30.06% to $114.0 million in 2024, then surged by 85.72% to $211.6 million in 2025, then gained by 12.04% to $237.1 million in 2026.
- The last three Assets Average figures came in at $237.1 million (Q1 2026), $211.6 million (Q4 2025), and $186.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 237.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 237.13 Mn |
| Dec 31, 2025 | 211.65 Mn |
| Sep 30, 2025 | 186.56 Mn |
| Jun 30, 2025 | 163.98 Mn |
| Mar 31, 2025 | 116.62 Mn |
| Dec 31, 2024 | 113.96 Mn |
| Sep 30, 2024 | 116.06 Mn |
| Jun 30, 2024 | 114.64 Mn |
| Mar 31, 2024 | 136.63 Mn |
| Dec 31, 2023 | 162.94 Mn |
| Sep 30, 2023 | 183.96 Mn |
| Jun 30, 2023 | 156.32 Mn |
| Mar 31, 2023 | 107.96 Mn |
| Dec 31, 2022 | 103.07 Mn |
| Sep 30, 2022 | 105.75 Mn |
| Jun 30, 2022 | 108.28 Mn |
| Mar 31, 2022 | 112.41 Mn |
| Dec 31, 2021 | 110.27 Mn |
| Sep 30, 2021 | 117.88 Mn |
| Jun 30, 2021 | 130.40 Mn |
| Mar 31, 2021 | 145.63 Mn |
| Dec 31, 2020 | 186.06 Mn |
| Sep 30, 2020 | 208.15 Mn |
| Jun 30, 2020 | 203.34 Mn |
| Mar 31, 2020 | 176.60 Mn |
| Dec 31, 2019 | 168.82 Mn |
| Sep 30, 2019 | 205.57 Mn |
| Jun 30, 2019 | 230.95 Mn |
| Mar 31, 2019 | 260.30 Mn |
| Dec 31, 2018 | 230.20 Mn |
| Sep 30, 2018 | 178.04 Mn |
| Jun 30, 2018 | 120.66 Mn |
| Mar 31, 2018 | 79.10 Mn |
| Dec 31, 2017 | 76.47 Mn |
| Sep 30, 2017 | 62.49 Mn |
| Jun 30, 2017 | 69.04 Mn |
| Mar 31, 2017 | 79.94 Mn |
| Dec 31, 2016 | 86.34 Mn |
| Sep 30, 2016 | 92.23 Mn |
| Jun 30, 2016 | 98.99 Mn |
| Mar 31, 2016 | 107.83 Mn |
| Dec 31, 2015 | 118.38 Mn |
| Sep 30, 2015 | 129.68 Mn |
| Jun 30, 2015 | 138.85 Mn |
| Mar 31, 2015 | 120.33 Mn |
| Dec 31, 2014 | 98.27 Mn |
| Sep 30, 2014 | 102.61 Mn |
| Jun 30, 2014 | 111.53 Mn |
| Mar 31, 2014 | 120.49 Mn |
| Dec 31, 2013 | 128.85 Mn |
| Sep 30, 2013 | 106.20 Mn |
| Jun 30, 2013 | 83.10 Mn |
| Mar 31, 2013 | 89.58 Mn |
| Dec 31, 2012 | 95.88 Mn |
| Sep 30, 2012 | 102.25 Mn |
| Jun 30, 2012 | 108.18 Mn |
| Mar 31, 2012 | 84.87 Mn |